AGENHIGH SIGNALFINANCIAL10-K

AGEN experienced a dramatic cash depletion of 93% alongside a massive 1,176% revenue spike, indicating either a major business transformation or potential liquidity crisis.

The company's cash position collapsed from $40.4M to just $3M while current liabilities surged 46% to $323.5M, creating an immediate liquidity concern that could threaten operations. Despite the extraordinary revenue growth to $42.9M, the severe cash drain combined with increased liabilities suggests either a major strategic pivot, asset monetization, or working capital crisis that requires immediate attention from investors.

Comparing 2026-03-16 vs 2025-03-17View on EDGAR →
FINANCIAL ANALYSIS

AGEN shows extreme financial volatility with revenue exploding over 1,000% to $42.9M while cash reserves nearly disappeared, falling 93% to just $3M against $323.5M in current liabilities. Operating losses improved significantly due to halved R&D spending ($155.5M to $79.3M), but the dramatic cash depletion alongside surging liabilities creates an urgent liquidity situation. The massive revenue increase appears insufficient to offset the severe deterioration in the balance sheet, suggesting either a major business restructuring or potential financial distress that demands immediate investor scrutiny.

FINANCIAL STATEMENT CHANGES
Revenue
P&L
+1176.5%
$3.4M$42.9M

Strong top-line growth of 1176.5% — accelerating demand or successful expansion into new markets.

Accounts Receivable
Balance Sheet
+349.9%
$407K$1.8M

Receivables surged 349.9% — revenue recognized but not yet collected; watch for collection issues or channel stuffing.

Current Assets
Balance Sheet
+192.8%
$45.6M$133.4M

Current assets grew 192.8% — improving short-term liquidity or inventory/receivables build.

Capital Expenditure
Cash Flow
-99%
$576K$6K

Capex reduced 99% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Cash & Equivalents
Balance Sheet
-92.6%
$40.4M$3.0M

Cash declined 92.6% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.

Operating Income
P&L
+83.3%
-$120.5M-$20.2M

Operating leverage kicking in — revenue growth outpacing cost growth, a hallmark of scaling businesses.

Operating Cash Flow
Cash Flow
+51.2%
-$158.3M-$77.2M

Operating cash flow surged 51.2% — exceptional cash generation, highest quality earnings signal.

R&D Expense
P&L
-49%
$155.5M$79.3M

R&D spending cut 49% — could signal cost discipline or concerning reduction in innovation investment.

Interest Expense
P&L
-48%
$2.4M$1.3M

Interest expense declined — debt repayment or refinancing at lower rates improving earnings quality.

Current Liabilities
Balance Sheet
+46.1%
$221.4M$323.5M

Current liabilities surged 46.1% — significant near-term obligations; verify ability to meet short-term debt.

LANGUAGE CHANGES
NEW — 2026-03-16
PRIOR — 2025-03-17
ADDED
There were 38,398,354 shares of the registrant s Common Stock outstanding as of March 12, 2026.
B usiness Our Business Agenus is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious disease.
Our primary business is immuno-oncology ("I-O"), where we are advancing antibody-based programs to activate innate and adaptive immunity, overcome tumor immune evasion and expand the population of patients who may benefit from immunotherapy.
Our lead clinical program is botensilimab ( BOT or AGEN1181 ), alone and in combination with balstilimab ( BAL ).
We also maintain select clinical-stage immuno-oncology assets, which may be used as standalone agents or be complimentary to botensilimab plus balstilimab ( BOT/BAL ).
+7 more — sign up free →
REMOVED
There were 25,308,841 shares of the registrant s Common Stock outstanding as of March 13, 2025.
B usiness Our Business We are a clinical-stage biotechnology company specializing in discovering and developing therapies to activate the body's immune system against cancer and infections.
Our pipeline includes immune-modulatory antibodies, adoptive cell therapies (via MiNK Therapeutics, Inc.
Our primary focus is immuno-oncology ( I-O ), and our diverse pipeline is supported by our in-house capabilities, including current good manufacturing practice ( cGMP ) manufacturing and a clinical operations platform.
We are a vertically integrated biotechnology company equipped with a suite of technology platforms to advance from novel target identification through manufacturing for clinical trials of antibodies and cell therapies.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →